Osteoarthritis

Dr. John Cush Tweet
@RheumNow
Yale researchers propose repurposing the epilepsy drug, lacosamide, to treat osteoarthritis. In animal models, delivered as a hydrogel conjugate IA, improved cartilage repair, slowed deterioration, & reduced pain. Chosen as it blocks Sodium channels, esp Nav1.7 involved in pain https://t.co/ERJ2xPEyzl
Dr. John Cush Tweet
@RheumNow
? value of FamHx in Rheum evals? My bias is that few Dz are heritable - #Ank Spondylitis, #gout, DIP Osteoarthritis! But literature says there's high heritability for SLE, RA, systemic sclerosis, Sjögren's, & autoimmune endocrinopathies. WHAT do you think? https://t.co/WGyQqpY1qX
Dr. John Cush Tweet
@RheumNow
Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis The NEJM reports that retatrutide, an investigational incretin agent, was shown to yield up to 25% weight reduction, with subanalyses also showing reduced pain with knee osteoarthritis, and less https://t.co/18DM2UL6vB
Dr. John Cush Tweet
@RheumNow
Remission — believe it or not. What’s happening in rheumatology this week? Dr. Jack Cush breaks down the latest news and journal reports on RheumNow: 10-year T2T data: 82% in remission Residual steroids don’t preserve remission Biologics linked to lower PsA risk GLP-1s + knee OA https://t.co/2Zf9g1Wehg
Dr. John Cush Tweet
@RheumNow
Supervised Physiotherapy Wins after ACL Repair The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with https://t.co/8HWmkmIexr
Dr. John Cush Tweet
@RheumNow
The Friday RheumNow podcast has dropped! In this week's episode, "Rheumatology Pay Up," Dr. Jack Cush covers: • Rheumatology physician pay rose 10.4% year-over-year • New data on colchicine and tofacitinib in knee OA • What a new study tells us about earlier axSpA diagnosis https://t.co/oXsNruWnc2
Dr. John Cush Tweet
@RheumNow
CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). https://t.co/MPgLpr7LPP
Dr. John Cush Tweet
@RheumNow
Obesity management goes far beyond the number on the scale. Watch our Four Pillars of Weight Loss video series, part of this month’s The Obesity Imperative campaign. What Are the Four Pillars of Obesity Management? Building a Multidisciplinary Program for Obesity & Arthritis https://t.co/16v4JFVWWs
Article

ACR Updates Osteoarthritis Guidance

ACR

The American College of Rheumatology (ACR) has released updated clinical guidance for the treatment and management of osteoarthritis (OA) of the knee, hip, and hand. The evidence-based recommendations update the 2019 ACR/Arthritis Foundation guideline and are designed to support individualized,

Article

Weight Loss Improves Psoriatic Disease Substantially!

Jack Cush, MD

Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent improvement in both psoriasis and psoriatic arthritis.

Dr. John Cush Tweet
@RheumNow
Why does obesity worsen Rheumatic disease?
Article

Osteoarthritis, Obesity and GLP-1s

Tom Appleton, MD, PhD

We all know that osteoarthritis is the most common form of arthritis in the world, and that obesity is its most modifiable risk factor. What I really want to focus on is the role that GLP-! receptor agonists might be playing in our management of osteoarthritis. So why does this matter?

Recent Blogs

rheumthought

Treatment for Obesity and Inflammation, but at what Cost?

Jonathan Kay, MD
Kay RT cover still

The costs of GLP-1 agonists must come down in order to make these treatments available to the people who need them - including many people with rheumatologic diseases. 

Read Article

Best of 2023: PMR: glad or bad tidings?

Sarah Mackie, MRCP, PhD
Smile feedback opinion yes no good back opinion
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on.
Read Post

PMR: glad or bad tidings?

Sarah Mackie, MRCP, PhD
Smile feedback opinion yes no good back opinion
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 Daily Podcasts Day2c

Topic Videos
×